SID 135264255 - PubChem
Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects - Kelly Kuk, Jennifer L. Taylor-Cousar, 2015
Impact of the CFTR-Potentiator Ivacaftor on Airway Microbiota in Cystic Fibrosis Patients Carrying A G551D Mutation | PLOS ONE
SID 24862788 - PubChem
101831-37-2 | Diclazuril | 2,6-Dichloro-α-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)-benzeneacetonitrile; Clinacox; Nuoqiu; P 64433; R 64433; Vecoxan; | C₁₇H₉Cl₃N₄O₂ | TRC
AIM | Treatment of Cystic Fibrosis
Pyrilutamide - Wikipedia
Case Study: Cystic Fibrosis
Ivacaftor - Wikipedia
Frontiers | Comprehensive Analysis of Chemical Structures That Have Been Tested as CFTR Activating Substances in a Publicly Available Database CandActCFTR
Elexacaftor - Wikipedia
Ivacaftor (VX 770, CAS Number: 873054-44-5) | Cayman Chemical
The impact of ivacaftor on sinonasal pathology in S1251N-mediated cystic fibrosis patients | PLOS ONE
Cystic Fibrosis Agents - LiverTox - NCBI Bookshelf
Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure–Activity and Structure–Property Relationship Studies | Journal of Medicinal Chemistry
Ivacaftor carboxylate | C24H26N2O5 - PubChem
The magnitude of ivacaftor effects on fluid secretion via R117H-CFTR channels: Human in vivo measurements | PLOS ONE
Lumacaftor/ivacaftor - Wikipedia
Lumacaftor/ivacaftor - Wikipedia
Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects - Kelly Kuk, Jennifer L. Taylor-Cousar, 2015
KAFTRIO (ivacaftor/tezacaftor/elexacaftor) - Wiki | Golden
Frontiers | CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine
Glycemia and β-cell function before and after elexacaftor/tezacaftor/ ivacaftor in youth and adults with cystic fibrosis - ScienceDirect
New Drug Approvals 2012 - Pt. V - Ivacaftor (Kalydeco TM )
Ivacaftor | C24H28N2O3 - PubChem
